台股 » 個股 » 國邑* » 籌碼相關 » 券商分點績效

國邑*

(6875)
  • 股價
    45.90
  • 漲跌
    ▼2.70
  • 漲幅
    -5.56%
  • 成交量
    550
  • 產業
    上櫃 生技醫療類股
  • 10人加入追蹤

    立即追蹤

  • 本地時間:13:30

     
國邑* (6875)籌碼相關-券商分點績效/獲利分析
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

«前一日     2026/01/19     後一日»

券商獲利排行 - 2026/01/19

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  6.69%285.42.3283.1-76108649.649.449.645.9
  7.10%281-0.8281.9-7918049.550.349.545.9
  7.68%202.20202.2-5305349.7049.745.9
  8.62%177.50177.5-4104150.2050.245.9
  6.55%140.613.1127.5-30134349.949.150.245.9
  6.39%84.6084.6-270274904945.9
  6.34%62.1062.1-200204904945.9
  6.89%33.9033.9-1001049.3049.345.9
  3.14%29.613.216.4-4151949.649.15045.9
  10.70%16.5016.5-30351.4051.445.9
  5.95%14.70.114.6-41549.549.549.645.9
  7.27%14.4014.4-40449.5049.545.9
  6.59%13.11.112-31449.748.849.945.9
  6.43%12.6012.6-40449.1049.145.9
  4.93%12.1-0.312.4-31549.149.34945.9
  4.61%11.30.810.5-32549.34949.445.9
  8.11%8.108.1-2025005045.9
  7.27%7.207.2-20249.5049.545.9
  7.27%7.207.2-20249.5049.545.9
  6.90%6.806.8-20249.3049.345.9
  4.37%6.5-0.67.1-21349.650.149.545.9
  3.80%5.61.73.9-12349.54949.945.9
  5.24%5.21.14.1-11249.648.95045.9
  8.02%404-10149.9049.945.9
  7.27%3.603.6-10149.5049.545.9
  7.27%3.603.6-10149.5049.545.9
  7.11%3.503.5-10149.4049.445.9
  7.09%3.503.5-10149.4049.445.9
  6.90%3.403.4-10149.3049.345.9
  6.90%3.403.4-10149.3049.345.9
  6.90%3.403.4-10149.3049.345.9
  6.90%3.403.4-10149.3049.345.9
  6.80%3.303.3-10149.3049.345.9
  1.77%1.81.8002249.54949.945.9
  1.01%0.50.5001149.849.55045.9
   00000049.949.9045.9
   00000050.2050.245.9
   00000049.549.5045.9
   00000049.749.7045.9
   00000049.649.6045.9
   00000049.449.4045.9
   00000049.649.6045.9
   0000004904945.9
   00000049.349.3045.9
   00000049.349.3045.9
   0000004949045.9
   00000049.5049.545.9
   00000049.249.2045.9
   00000049.5049.545.9
   00000049.449.4045.9

券商虧損排行 - 2026/01/19

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  -8.95%-171.8-1-170.83738150.550.549.545.9
  -6.67%-790.5-79.52324149.449.449.945.9
  -8.51%-72.60-72.61717050.250.2045.9
  -7.83%-58.50-58.51515049.849.8045.9
  -1.43%-55.1-51.1-41787749.649.949.245.9
  -7.53%-44.80-44.81112049.749.649.945.9
  -8.57%-430-431010050.250.2045.9
  -7.40%-36.70-36.71010049.649.6045.9
  -7.08%-34.90-34.91010049.449.4045.9
  -6.33%-310-31101004949045.9
  -9.22%-23.30-23.355050.650.6045.9
  -7.80%-23.30-23.366049.849.8045.9
  -6.57%-22.60-22.677049.149.1045.9
  -7.10%-210-2166049.449.4045.9
  -9.82%-200-2044050.950.9045.9
  -7.10%-17.50-17.555049.449.4045.9
  -8.11%-16.20-16.24405050045.9
  -6.42%-15.70-15.755049.149.1045.9
  -6.33%-15.50-15.55504949045.9
  -6.27%-15.30-15.35504949045.9
  -9.23%-140-1433050.650.6045.9
  -6.99%-13.80-13.844049.449.4045.9
  -6.90%-13.60-13.644049.349.3045.9
  -5.19%-12.70.1-12.945149.149.149.345.9
  -6.42%-12.60-12.644049.149.1045.9
  -6.23%-12.20-12.24404949045.9
  -7.74%-11.50-11.533049.849.8045.9
  -7.65%-11.40-11.433049.749.7045.9
  -5.68%-11.30.2-11.534149.849.749.945.9
  -7.34%-10.90-10.933049.549.5045.9
  -6.99%-10.30-10.333049.449.4045.9
  -6.96%-10.30-10.333049.349.3045.9
  -6.96%-10.30-10.333049.349.3045.9
  -5.17%-10.20.4-10.734149.649.549.945.9
  -6.90%-10.20-10.233049.349.3045.9
  -6.77%-100-1033049.249.2045.9
  -6.55%-9.60-9.633049.149.1045.9
  -6.52%-9.60-9.633049.149.1045.9
  -6.45%-9.50-9.533049.149.1045.9
  -9.02%-9.10-9.122050.550.5045.9
  -6.20%-9.10-9.133048.948.9045.9
  -8.57%-8.60-8.622050.250.2045.9
  -8.20%-8.20-8.22205050045.9
  -8.15%-8.10-8.12205050045.9
  -8.02%-80-822049.949.9045.9
  -3.22%-7.91.6-9.635249.349.149.945.9
  -7.92%-7.90-7.922049.949.9045.9
  -7.74%-7.70-7.722049.849.8045.9
  -7.41%-7.30-7.322049.649.6045.9
  -7.27%-7.20-7.222049.549.5045.9
國邑*用於PH-ILD臨床三期試驗藥品出貨 明年啟動收案Anue鉅亨-2025/12/08
國邑*授權夥伴將公布L606新藥臨床成果 年底前啟動PH-ILD全球三期Anue鉅亨-2025/08/14
國邑* 相關文章
國邑* 相關影音